Global Microbiome Therapeutics Supply, Demand and Key Producers, 2026-2032
Description
The global Microbiome Therapeutics market size is expected to reach $ 4251 million by 2032, rising at a market growth of 29.8% CAGR during the forecast period (2026-2032).
Microbiome Therapeutics refers to novel therapeutic approaches that utilize modulation of the human microbiome—especially gut microbiota—to treat or prevent diseases. These therapies include live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT), engineered bacteria, and microbiota-derived metabolites aimed at rebalancing microbial ecosystems. They are being developed for a wide range of conditions, including metabolic disorders, immune dysfunction, neurological diseases, inflammatory bowel disease (IBD), and as adjuncts to cancer immunotherapy. Compared to traditional pharmaceuticals, microbiome-based therapies offer high specificity, personalization, and long-term safety, making them the “fourth therapeutic modality” following small molecules, biologics, and cell/gene therapies.
As the global push for personalized medicine, chronic disease management, and immune-oncology adjunct therapies gains momentum, microbiome therapeutics is entering a critical commercialization window. Regulatory agencies such as the FDA and EMA are streamlining approval pathways for live biotherapeutic products (LBPs), while landmark approvals of Rebyota and Vowst mark a turning point. Strategic alliances between biotech startups and global pharma are accelerating late-stage clinical programs, supported by both capital and platform synergies.
Despite its transformative potential, the microbiome therapeutics sector faces multiple uncertainties. Manufacturing and regulatory frameworks remain inconsistent across countries, slowing clinical translation. Microbiota therapies face inherent variability and complexity, posing challenges in standardizing efficacy and trial design. Technical bottlenecks in sample sourcing, cold-chain logistics, and microbial viability maintenance elevate development costs. Additionally, market education and patient acceptance still require time, particularly in emerging regions like Asia, where applications are largely limited to early-stage R&D and clinical trials.
Demand is expanding beyond gastrointestinal conditions into systemic diseases such as IBD, recurrent Clostridioides difficile infection (CDI), cancer immunotherapy, Parkinson’s, and autism spectrum disorders. Partnerships between CROs and pharma are intensifying, while genomics, metabolomics, and AI are enabling high-throughput microbial strain screening. The clinical sector is seeking more reproducible, orally deliverable LBPs and microbiome-derived metabolite products, which align with industrial scalability. With public and private insurers beginning to cover these new modalities, microbiome therapeutics is on the path to becoming a standard pillar of precision medicine.
This report studies the global Microbiome Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Microbiome Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Microbiome Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Microbiome Therapeutics total market, 2021-2032, (USD Million)
Global Microbiome Therapeutics total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Microbiome Therapeutics total market, key domestic companies, and share, (USD Million)
Global Microbiome Therapeutics revenue by player, revenue and market share 2021-2026, (USD Million)
Global Microbiome Therapeutics total market by Type, CAGR, 2021-2032, (USD Million)
Global Microbiome Therapeutics total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Microbiome Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Finch Therapeutics, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, Ferring, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Microbiome Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Microbiome Therapeutics Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Microbiome Therapeutics Market, Segmentation by Type:
Upper GIT
Lower GIT
Global Microbiome Therapeutics Market, Segmentation by Application:
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Companies Profiled:
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Finch Therapeutics
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
Ferring
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Vedanta Biosciences
Metabogen
Key Questions Answered
1. How big is the global Microbiome Therapeutics market?
2. What is the demand of the global Microbiome Therapeutics market?
3. What is the year over year growth of the global Microbiome Therapeutics market?
4. What is the total value of the global Microbiome Therapeutics market?
5. Who are the Major Players in the global Microbiome Therapeutics market?
6. What are the growth factors driving the market demand?
Microbiome Therapeutics refers to novel therapeutic approaches that utilize modulation of the human microbiome—especially gut microbiota—to treat or prevent diseases. These therapies include live biotherapeutic products (LBPs), fecal microbiota transplantation (FMT), engineered bacteria, and microbiota-derived metabolites aimed at rebalancing microbial ecosystems. They are being developed for a wide range of conditions, including metabolic disorders, immune dysfunction, neurological diseases, inflammatory bowel disease (IBD), and as adjuncts to cancer immunotherapy. Compared to traditional pharmaceuticals, microbiome-based therapies offer high specificity, personalization, and long-term safety, making them the “fourth therapeutic modality” following small molecules, biologics, and cell/gene therapies.
As the global push for personalized medicine, chronic disease management, and immune-oncology adjunct therapies gains momentum, microbiome therapeutics is entering a critical commercialization window. Regulatory agencies such as the FDA and EMA are streamlining approval pathways for live biotherapeutic products (LBPs), while landmark approvals of Rebyota and Vowst mark a turning point. Strategic alliances between biotech startups and global pharma are accelerating late-stage clinical programs, supported by both capital and platform synergies.
Despite its transformative potential, the microbiome therapeutics sector faces multiple uncertainties. Manufacturing and regulatory frameworks remain inconsistent across countries, slowing clinical translation. Microbiota therapies face inherent variability and complexity, posing challenges in standardizing efficacy and trial design. Technical bottlenecks in sample sourcing, cold-chain logistics, and microbial viability maintenance elevate development costs. Additionally, market education and patient acceptance still require time, particularly in emerging regions like Asia, where applications are largely limited to early-stage R&D and clinical trials.
Demand is expanding beyond gastrointestinal conditions into systemic diseases such as IBD, recurrent Clostridioides difficile infection (CDI), cancer immunotherapy, Parkinson’s, and autism spectrum disorders. Partnerships between CROs and pharma are intensifying, while genomics, metabolomics, and AI are enabling high-throughput microbial strain screening. The clinical sector is seeking more reproducible, orally deliverable LBPs and microbiome-derived metabolite products, which align with industrial scalability. With public and private insurers beginning to cover these new modalities, microbiome therapeutics is on the path to becoming a standard pillar of precision medicine.
This report studies the global Microbiome Therapeutics demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Microbiome Therapeutics, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Microbiome Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Microbiome Therapeutics total market, 2021-2032, (USD Million)
Global Microbiome Therapeutics total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Microbiome Therapeutics total market, key domestic companies, and share, (USD Million)
Global Microbiome Therapeutics revenue by player, revenue and market share 2021-2026, (USD Million)
Global Microbiome Therapeutics total market by Type, CAGR, 2021-2032, (USD Million)
Global Microbiome Therapeutics total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Microbiome Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Finch Therapeutics, PureTech, Synlogic, Enterome BioScience, 4D Pharma, Second Genome, Ferring, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Microbiome Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Microbiome Therapeutics Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Microbiome Therapeutics Market, Segmentation by Type:
Upper GIT
Lower GIT
Global Microbiome Therapeutics Market, Segmentation by Application:
C. difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Orphan Drug
Immuno-oncology
Others
Companies Profiled:
Seres Therapeutics
Assembly Biosciences
Synthetic Biologics
Finch Therapeutics
PureTech
Synlogic
Enterome BioScience
4D Pharma
Second Genome
Ferring
C3 Jian
Rebiotix
MicroBiome Therapeutics LLC
Metabiomics
Ritter Pharmaceuticals
Symberix
OpenBiome
Azitra
Symbiotix Biotherapies
Vedanta Biosciences
Metabogen
Key Questions Answered
1. How big is the global Microbiome Therapeutics market?
2. What is the demand of the global Microbiome Therapeutics market?
3. What is the year over year growth of the global Microbiome Therapeutics market?
4. What is the total value of the global Microbiome Therapeutics market?
5. Who are the Major Players in the global Microbiome Therapeutics market?
6. What are the growth factors driving the market demand?
Table of Contents
169 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Microbiome Therapeutics Companies Competitive Analysis
- 4 United States VS China VS Rest of World (by Headquarter Location)
- 5 Market Analysis by Type
- 6 Market Analysis by Application
- 7 Company Profiles
- 8 Industry Chain Analysis
- 9 Research Findings and Conclusion
- 10 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
